PLCB2 (phospholipase C beta 2) is a key signaling enzyme that catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate to generate the second messengers diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) 1. The enzyme functions downstream of G protein-coupled receptors (GPCRs) and plays critical roles in neutrophil activation, where it promotes RASGRP4 activation by DAG to facilitate neutrophil functional responses 2. PLCB2 serves as a positive regulator of VEGF-induced vascular permeability by controlling calcium flux and phosphatidylinositol 4,5-bisphosphate levels 3. In disease contexts, PLCB2 expression is reduced in ulcerative colitis, where its restoration inhibits colonic epithelial cell pyroptosis 4. Conversely, PLCB2 knockdown in melanoma cells reduces viability and promotes apoptosis by suppressing Ras/Raf/MAPK signaling 5. The enzyme is also essential for platelet activation responses, with its expression regulated by nuclear factor-κB 6. PLCB2 has emerged as a prognostic marker in clear-cell renal-cell carcinoma, associated with immune cell infiltration and treatment responses 7. These findings establish PLCB2 as a multifunctional enzyme with significant therapeutic implications across various pathological conditions.